Literature DB >> 27567694

Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients.

Josh Levitsky1, David Goldberg2, Abigail R Smith3, Sarah A Mansfield4, Brenda W Gillespie5, Robert M Merion6, Anna S F Lok7, Gary Levy8, Laura Kulik9, Michael Abecassis10, Abraham Shaked11.   

Abstract

BACKGROUND & AIMS: Acute rejection is detrimental to most transplanted solid organs, but is considered to be less of a consequence for transplanted livers. We evaluated risk factors for and outcomes after biopsy-proven acute rejection (BPAR) based on an analysis of a more recent national sample of recipients of liver transplants from living and deceased donors.
METHODS: We analyzed data from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) from 2003 through 2014 as the exploratory cohort and the Scientific Registry of Transplant Recipients (SRTR) from 2005 through 2013 as the validation cohort. We examined factors associated with time to first BPAR using multivariable Cox regression or discrete-survival analysis. Competing risks methods were used to compare causes of death and graft failure between recipients of living and deceased donors.
RESULTS: At least 1 BPAR episode occurred in 239 of 890 recipients in A2ALL (26.9%) and 7066 of 45,423 recipients in SRTR (15.6%). In each database, risk of rejection was significantly lower when livers came from biologically related living donors (A2ALL hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.43-0.76; and SRTR HR, 0.78; 95% CI, 0.66-0.91) and higher in liver transplant recipients with primary biliary cirrhosis, of younger age, or with hepatitis C. In each database, BPAR was associated with significantly higher risks of graft failure and death. The risks were highest in the 12 month post-BPAR period in patients whose first episode occurred more than 1 year after liver transplantation: HRs for graft failure were 6.79 in A2ALL (95% CI, 2.64-17.45) and 4.41 in SRTR (95% CI, 3.71-5.23); HRs for death were 8.81 in A2ALL (95% CI, 3.37-23.04) and 3.94 in SRTR (95% CI, 3.22-4.83). In analyses of cause-specific mortality, associations were observed for liver-related (graft failure) causes of death but not for other causes.
CONCLUSIONS: Contrary to previous data, acute rejection after liver transplant is associated with significantly increased risk of graft failure, all-cause mortality, and graft failure-related death, regardless of primary liver disease etiology. Living donor liver transplantation from a biologically related donor is associated with decreased risk of rejection.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Database Analysis; LT; Risk Factor; Survival

Mesh:

Year:  2016        PMID: 27567694      PMCID: PMC5326609          DOI: 10.1016/j.cgh.2016.07.035

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  30 in total

1.  Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

Authors:  Mylène Sebagh; Didier Samuel; Teresa Maria Antonini; Audrey Coilly; Davide Degli Esposti; Bruno Roche; Vincent Karam; Alexandre Dos Santos; Jean-Charles Duclos-Vallée; Anne-Marie Roque-Afonso; Eric Ballot; Catherine Guettier; Frédérique Blandin; Faouzi Saliba; Daniel Azoulay
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

2.  Immunosuppressive therapy and tolerance of organ allografts.

Authors:  Thomas E Starzl
Journal:  N Engl J Med       Date:  2008-01-24       Impact factor: 91.245

3.  What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; K Abu-Elmagd; T Starzl; J Fung
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

4.  Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.

Authors:  M Charlton; E Seaberg
Journal:  Liver Transpl Surg       Date:  1999-07

5.  Histologic characteristics of late cellular rejection, significance of centrilobular injury, and long-term outcome in pediatric liver transplant recipients.

Authors:  Shikha S Sundaram; Hector Melin-Aldana; Katie Neighbors; Estella M Alonso
Journal:  Liver Transpl       Date:  2006-01       Impact factor: 5.799

6.  The role of donor-specific HLA alloantibodies in liver transplantation.

Authors:  J G O'Leary; A J Demetris; L S Friedman; H M Gebel; P F Halloran; A D Kirk; S J Knechtle; S V McDiarmid; A Shaked; P I Terasaki; K J Tinckam; S J Tomlanovich; K J Wood; E S Woodle; A A Zachary; G B Klintmalm
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

7.  Defining long-term outcomes with living donor liver transplantation in North America.

Authors:  Kim M Olthoff; Abigail R Smith; Michael Abecassis; Talia Baker; Jean C Emond; Carl L Berg; Charlotte A Beil; James R Burton; Robert A Fisher; Chris E Freise; Brenda W Gillespie; David R Grant; Abhinav Humar; Igal Kam; Robert M Merion; Elizabeth A Pomfret; Benjamin Samstein; Abraham Shaked
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

8.  Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation.

Authors:  Jacob Alexander; James D Lord; Matthew M Yeh; Carlos Cuevas; Ramasamy Bakthavatsalam; Kris V Kowdley
Journal:  Liver Transpl       Date:  2008-02       Impact factor: 5.799

9.  Reliability and predictive value of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database nomenclature and grading system for cellular rejection of liver allografts.

Authors:  A J Demetris; E C Seaberg; K P Batts; L D Ferrell; J Ludwig; R S Markin; S H Belle; K Detre
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

Review 10.  A need for biomarkers of operational tolerance in liver and kidney transplantation.

Authors:  M-C Londoño; R Danger; M Giral; J-P Soulillou; A Sánchez-Fueyo; S Brouard
Journal:  Am J Transplant       Date:  2012-04-04       Impact factor: 8.086

View more
  41 in total

1.  Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial.

Authors:  Khurram Bari; Shimul A Shah; Tiffany E Kaiser; Robert M Cohen; Nadeem Anwar; David Kleesattel; Kenneth E Sherman
Journal:  Liver Transpl       Date:  2020-08-19       Impact factor: 5.799

2.  Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Authors:  Varun Saxena; Vandana Khungar; Elizabeth C Verna; Josh Levitsky; Robert S Brown; Mohamed A Hassan; Mark S Sulkowski; Jacqueline G O'Leary; Farrukh Koraishy; Joseph S Galati; Alexander A Kuo; Monika Vainorius; Lucy Akushevich; David R Nelson; Michael W Fried; Norah Terrault; K Rajender Reddy
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

3.  The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis.

Authors:  Yuval A Patel; Jacqueline B Henson; Julius M Wilder; Jiayin Zheng; Schein-Chung Chow; Carl L Berg; Stuart J Knechtle; Andrew J Muir
Journal:  Clin Transplant       Date:  2018-09-15       Impact factor: 2.863

4.  Outcomes of Liver Transplantation Among Older Recipients With Nonalcoholic Steatohepatitis in a Large Multicenter US Cohort: the Re-Evaluating Age Limits in Transplantation Consortium.

Authors:  Allison J Kwong; Deepika Devuni; Connie Wang; Justin Boike; Jennifer Jo; Lisa VanWagner; Marina Serper; Lauren Jones; Rajani Sharma; Elizabeth C Verna; Julia Shor; Margarita N German; Alexander Hristov; Alexander Lee; Erin Spengler; Ayman A Koteish; Gurbir Sehmbey; Anil Seetharam; Nimy John; Yuval Patel; Matthew R Kappus; Thomas Couri; Sonali Paul; Reena J Salgia; Quan Nhu; Catherine T Frenette; Jennifer C Lai; Aparna Goel
Journal:  Liver Transpl       Date:  2020-10-13       Impact factor: 5.799

5.  Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients.

Authors:  Mohammad Bilal Siddiqui; Samarth Patel; Chandra Bhati; Trevor Reichman; Kenyada Williams; Carolyn Driscoll; Erika Liptrap; Mary E Rinella; Richard K Sterling; M Shadab Siddiqui
Journal:  Transplant Proc       Date:  2019 Jul - Aug       Impact factor: 1.066

6.  The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes.

Authors:  Therese Bittermann; Rebecca A Hubbard; James D Lewis; David S Goldberg
Journal:  Am J Transplant       Date:  2019-07-17       Impact factor: 8.086

7.  Proteoforms in Peripheral Blood Mononuclear Cells as Novel Rejection Biomarkers in Liver Transplant Recipients.

Authors:  T K Toby; M Abecassis; K Kim; P M Thomas; R T Fellers; R D LeDuc; N L Kelleher; J Demetris; J Levitsky
Journal:  Am J Transplant       Date:  2017-06-27       Impact factor: 8.086

8.  Exploring pre-surgery donor-specific antibodies in the context of organ shortage in liver transplant.

Authors:  Savio G Barreto; Mark E Brooke-Smith; Eu Ling Neo; Paul Dolan; Richard Leibbrandt; Tim Emery; Robert Carroll; Alan Wigg; John W Chen
Journal:  Langenbecks Arch Surg       Date:  2019-11-20       Impact factor: 3.445

9.  Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.

Authors:  Allison J Kwong; Anji Wall; Marc Melcher; Uerica Wang; Aijaz Ahmed; Aruna Subramanian; Paul Y Kwo
Journal:  Am J Transplant       Date:  2018-11-26       Impact factor: 8.086

10.  Healthcare utilization after liver transplantation is highly variable among both centers and recipients.

Authors:  T Bittermann; R A Hubbard; M Serper; J D Lewis; S F Hohmann; L B VanWagner; D S Goldberg
Journal:  Am J Transplant       Date:  2017-11-17       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.